{"entity":{"id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","aka":[],"tldr":"A phase 2 trial of Carfilzomib, Venetoclax, Dexamethasone in multiple myeloma, run by AbbVie, active and no longer recruiting.","summary":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) is a phase 2 interventional study registered as NCT02899052 by AbbVie, with 120 participants planned, started 2017-01-19 and due to reach its primary completion in 2027-06. Interventions recorded: Carfilzomib, Venetoclax, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02899052","url":"https://clinicaltrials.gov/study/NCT02899052"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["antiemetic-therapy","bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["carfilzomib","venetoclax","dexamethasone"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02899052","phase":"2","setting":"A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","started":"2017-01-19","startedType":"actual","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02899052/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"},{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}